The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research
NCT03158090 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1965
Last updated 2022-03-16
Summary
This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.
Conditions
Interventions
- PROCEDURE
-
Transnasal butterfly surgery
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
- DRUG
-
sandostatin
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
- RADIATION
-
radiotherapy
The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Sponsors & Collaborators
-
Ginkgo Leaf Center for Rare Disorders
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-15
- Primary Completion
- 2050-12-30
- Completion
- 2051-01-30
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
NCT01278342 ·Status: COMPLETED ·Phase: PHASE4
-
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
NCT02354508 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
NCT01618513 ·Status: COMPLETED ·Phase: PHASE4
-
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
NCT01995734 ·Status: APPROVED_FOR_MARKETING
-
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
NCT01029275 ·Status: COMPLETED ·Phase: NA
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
The Treatment and Natural History of Acromegaly
NCT00001981 ·Status: COMPLETED
-
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
NCT00171730 ·Status: COMPLETED ·Phase: PHASE2
-
Late Effects of Radiosurgery on Acromegaly Study
NCT02296216 ·Status: COMPLETED ·Phase: NA
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED
-
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00690898 ·Status: COMPLETED ·Phase: PHASE3
-
Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
NCT00993356 ·Status: UNKNOWN ·Phase: PHASE2
-
Surgical Versus Medical Treatment of Acromegaly
NCT01000090 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
NCT01283542 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00225979 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Sandostatin LAR® in Acromegaly
NCT01424241 ·Status: COMPLETED ·Phase: PHASE4
-
Diet in the Management of Acromegaly
NCT05401084 ·Status: RECRUITING ·Phase: NA
-
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
NCT03439709 ·Status: UNKNOWN ·Phase: PHASE3
-
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
NCT01861717 ·Status: TERMINATED ·Phase: PHASE4
-
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
NCT03249480 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00376064 ·Status: COMPLETED ·Phase: PHASE4
-
Acromegaly Combination Treatment Study
NCT01538966 ·Status: TERMINATED ·Phase: NA
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED